Amneal Pharmaceuticals
AMRX
278 hedge funds and large institutions have $1.95B invested in Amneal Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 100 increasing their positions, 80 reducing their positions, and 25 closing their positions.
611% more call options, than puts
Call options by funds: $7.01M | Put options by funds: $985K
132% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 25
33% more capital inflows, than outflows
Capital inflows: $190M | Capital outflows: $143M
25% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 80
12% more funds holding
Funds holding: 248 → 278 (+30)
1.16% more ownership
Funds ownership: 48% → 49.16% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$18.4M |
| 2 |
Morgan Stanley
New York
|
+$15M |
| 3 |
PFM Health Sciences
San Francisco,
California
|
+$12.7M |
| 4 |
D.E. Shaw & Co
New York
|
+$12.5M |
| 5 |
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$20.3M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$17.5M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.6M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$8.48M |
| 5 |
Walleye Capital
New York
|
-$8M |
AMRX Hedge Fund Activity: Q4 2025 in Review
278 of the 8,297 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2025, worth a combined $1.95B — up 29% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new AMRX positions and 25 closed out — a net gain of 33 holders — while 100 added to existing stakes and 80 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $18.4M. The largest seller was Nantahala Capital Management, cutting an estimated $20.3M.
- 278 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2025, up from 248 in Q3 2025.
- Funds reported $1.95B of Amneal Pharmaceuticals stock for Q4 2025, up 29% quarter-over-quarter.
- 58 funds opened new Amneal Pharmaceuticals positions in Q4 2025 and 25 closed out, a net change of +33 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2025 was Assenagon Asset Management, an estimated $18.4M added.
- The largest Amneal Pharmaceuticals seller in Q4 2025 was Nantahala Capital Management, an estimated $20.3M sold.
Based on aggregated 13F filings for Q4 2025.